AbbVie has showcased innovative developments in cancer treatment at the AACR Annual Meeting, contributing to its 4% price increase despite market volatility. The company's oncology advancements are expected to boost revenue and earnings, aligning with its strong long-term performance and shareholder return.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing